'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

(MedPage Today) -- The FDA approved the first-in-class RAS inhibitor daraxonrasib (Rasonque) for metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The approval stipulates use in adults with PDAC previously...